Validation of detecting monogenetic diseases & aneuploidy simultaneously by next generation sequencing with linkage analysis

Sijia Lu,Jie Qiao,Xiaoliang Sunney Xie

DOI: https://doi.org/10.1016/j.fertnstert.2016.07.473

IF: 6.7

2016-01-01

Fertility and Sterility

Abstract:Here we report three supportive cases by screening embryos with our well-established and published method, named “mutated allele revealed by sequencing with aneuploidy and linkage analyses” (MARSALA), which combines multiple annealing and looping based amplification cycles (MALBACTM) and Next Generation Sequencing with linkage analysis. The MARSALA strategy is able to detect aneuploidy and targeted gene mutations simultaneously in preimplantation genetic diagnosis (PGD) process during an in vitro fertilization (IVF) cycle. We sequence the genome of the parents and relatives carrying the monogenic disease allele with the depth of 2x genome coverage. Then, from the sequencing results of each embryo, the SNP readouts (heterozygous or homozygous) adjacent to the disease-cause mutation sites allowed the identification of the disease-carrying allele in the embryo. Blastocyst Biopsy We collected a few TE cells from each hatching blastocyst on day 5 or day 6. All embryos were obtained from patients who chose to be subjected to an IVF procedure and voluntarily gave their consent for providing the samples for this study. Single cell whole genome amplification (WGA) with MALBAC The WGA process was performed with the standard protocol provided by the commercial kit, MALBACTM Single Cell WGA Kit (Cat. #: YK001A/B, Yikon Genomics). For blood samples, we extracted the gDNA by using the QIAamp DNA Blood Mini Kit (QIAGEN) and amplified 1 ng gDNA using the MALBACTM Single Cell WGA Kit (Cat. #: YK001A/B, Yikon Genomics). MARSALA method Eight nano-grams of MALBAC products were used as the template for PCR reactions targeting disease-cause mutation sites. The PCR products was then added into the corresponding MALBAC products at 1-5%. The mixture was used to construct a sequencing library using the NEBNext Ultra DNA library Prep kit (New England Biolabs). The sequencing was done on the Illumina HiSeq 2500 platform with a low depth of 0.1x genome coverage. Following this procedure, targeted point mutations and aneuploidy can be detected simultaneously. 1. MARSALA analyses of blastocyst sequencing for case 1 in which both the husband and wife were carrying SLC26A4 mutations that cause autosomal recessive deaf.2. MARSALA analyses of blastocyst sequencing for case 2 in wife was affected by a PKD1 mutation that causes autosomal dominant polycystic kidney.3. MARSALA analyses of blastocyst sequencing for case 3 in wife was affected by the X chromosomal gene F8 that cause hemophilia A. We demonstrated that our streamlined MASALA method can simultaneously screen aneuploidy and monogenic diseases, accurately and cost-efficiently, combining the MALBACTM technology and NGS platform.